FDA’s widely expected rejection of Amgen Inc.’s Xgeva (denosumab) for a new oncology indication highlights the need for clinically meaningful endpoints in trials designed to expand the use of castration-resistant prostate cancer therapies into earlier disease stages.
FDA issued a “complete response” letter for Amgen’s supplemental BLA for prevention of bone metastases in high-risk patients with castrate-resistant...